CD19 and diffuse large B-cell lymphoma: The first-in-class CD19-targeted CAR-T tisagenlecleucel (also known as tisa-cel) was approved by the FDA for relapsed/refractory B-ALL in August 2017 and diffuse large B cell lymphoma (DLBCL) in May 2018, with overall remission rates of 83% and 52%, respectively [5,6].